High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer

doi:10.1002/14651858.CD007563.pub3

CORC > 兰州大学 > 兰州大学 > 基础医学院 > 期刊论文

	High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer
	Liu, RF; Wang, XH; Tian, JH; Yang, KH; Wang, J; Jiang, L; Hao, XY; Liu, RF (reprint author), Lanzhou Univ, Gansu Tumour Hosp, Radiat Oncol Ctr, 2 Xioaxihu East Rd, Lanzhou 730050, Gansu, Peoples R China.
刊名	COCHRANE DATABASE OF SYSTEMATIC REVIEWS
	2014
期号	10 页码:-
关键词	Brachytherapy [methods] Neoplasm Recurrence, Local Neoplasm Staging Radiotherapy Dosage Randomized Controlled Trials as Topic Uterine Cervical Neoplasms [mortality pathology radiotherapy] Female Humans
ISSN号	1469-493X
DOI	10.1002/14651858.CD007563.pub3
文献子类	Review
英文摘要	Background This is an updated version of the original Cochrane review published in 2010 (Issue 7). Carcinoma of the uterine cervix is the second most common cancer and the third leading cause of cancer death among women. Radiotherapy has been used successfully to treat cervical cancer for nearly a century. The combination of external beam radiotherapy (EBRT) and intracavity brachytherapy (ICBT) has become a standard treatment for cervical cancer. Whether high dose rate (HDR) or low dose rate (LDR) brachytherapy improves outcomes in terms of local control rates, survival and complications for women with cervical cancer remains controversial. Objectives To assess the efficacy and safety of HDR versus LDR ICBT in combination with EBRT for women with uterine cervical cancer. Search methods We searched the Cochrane Gynaecological Cancer Group Specialised Register and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2014, Issue 1), MEDLINE (1966 to March 2014), EMBASE (1974 to March 2014), and the Chinese Biomedical Literature Database (CBM) (1978 to March 2014) for relevant original, published trials. Selection criteria Randomised controlled trials (RCTs) and quasi-RCTs that compared HDR with LDR ICBT, combined with EBRT, for women with locally advanced uterine cervical cancer. Data collection and analysis Two authors independently extracted the data using standardised forms. Primary outcome measures included overall survival (OS), relapse-free survival (RFS) and pelvic control rate, while secondary outcomes included rates of recurrence and complications. Main results Four studies involving 1265 women met the inclusion criteria. In our meta-analysis to compare HDR and LDR ICBT, the pooled risk ratios (RRs) were 0.95 (95% confidence interval (CI) 0.79 to 1.15), 0.93 (95% CI 0.84 to 1.04) and 0.79 (95% CI 0.52 to 1.20) for 3, 5-and 10-year overall survival rates respectively; and 0.95 (95% CI 0.84 to 1.07) and 1.02 (0.88 to 1.19) for 5-and 10-year disease-specific survival (DSS) rates respectively. The RR for RFS was 1.04 (95% CI 0.71 to 1.52) and 0.96 (95% CI 0.81 to 1.14) at 3-and 5-years. For local control rates the RR was 0.95 (95% CI 0.86 to 1.05) and 0.95 (95% CI 0.87 to 1.05) at 3-and 5-years; with a RR of 1.09 (95% CI 0.83 to 1.43) for locoregional recurrence, 0.79 (95% CI 0.40 to 1.53) for local and distant recurrence, 2.23 (95% CI 0.78 to 6.34) for para-aortic lymph node metastasis, and 0.99 (95% CI 0.72 to 1.35) for distance metastasis. For bladder, rectosigmoid and small bowel complications, the RR was 1.33 (95% CI 0.53 to 3.34), 1.00 (95% CI 0.52 to 1.91) and 3.37 (95% CI 1.06 to 10.72) respectively. These results indicated that there were no significant differences except for increased small bowel complications with HDRs (P = 0.04). Authors' conclusions Since the last version of this review, no new studies were identified for inclusion in this review to provide additional information. This review showed no significant differences between HDR and LDR ICBT when considering OS, DSS, RFS, local control rate, recurrence, metastasis and treatment related complications for women with cervical carcinoma. Due to some potential advantages of HDR ICBT (rigid immobilization, outpatient treatment, patient convenience, accuracy of source and applicator positioning, individualized treatment) we recommend the use of HDR ICBT for all clinical stages of cervix cancer. The overall risk of bias was high for the included studies as many of the items were either of high or unclear risk. The GRADE assessment of the quality of the evidence was low to moderate.
学科主题	General & Internal Medicine
出版地	HOBOKEN
资助项目	甘肃省青年科技基金计划
项目编号	Radio-oncology Clinical Medicine Centre, Gansu Province ; science technology renovation team of tumour treatment using heavy ion of Lanzhou, China ; Youth fund plan, science and technology department of gansu province, China [145RJYA275]
语种	英语
WOS记录号	WOS:000347646000035
资助机构	GSSTD
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/121751]
专题	基础医学院_期刊论文
通讯作者	Liu, RF (reprint author), Lanzhou Univ, Gansu Tumour Hosp, Radiat Oncol Ctr, 2 Xioaxihu East Rd, Lanzhou 730050, Gansu, Peoples R China.
推荐引用方式 GB/T 7714	Liu, RF,Wang, XH,Tian, JH,et al. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS,2014(10):-.
APA	Liu, RF.,Wang, XH.,Tian, JH.,Yang, KH.,Wang, J.,...&Liu, RF .(2014).High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.COCHRANE DATABASE OF SYSTEMATIC REVIEWS(10),-.
MLA	Liu, RF,et al."High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer".COCHRANE DATABASE OF SYSTEMATIC REVIEWS .10(2014):-.